Tolododekin Alfa (ANK-101) and Anti-PD-1/PD-L1 Antibody Combination Treatment for Advanced Non-Small Cell Lung Cancer

This study focuses on testing a new combination of treatments for people with advanced non-small cell lung cancer (NSCLC). It looks at the effects of a drug called tolododekin alfa (ANK-101) when used with another type of medicine that targets proteins known as PD-1 or PD-L1, which are involved in how cancer cells evade the immune system. There are two groups involved: one group includes patients whose cancer has worsened after receiving the usual treatments, and the other group includes patients who have not yet received treatment for their advanced lung cancer. The goal is to find out if this new combination can provide better outcomes for patients who have limited options. Participants will receive the treatments as part of the study to see how well they work together. The study observes how the body responds to this combination and checks for any potential improvements in controlling the cancer. Researchers will closely monitor participants to understand the safety and effects of these medications, ensuring that any risks are managed and any benefits are maximized. Although specific outcomes are not listed, the study aims to gather essential information to inform future treatments for lung cancer.